Glucose (Dextrose)

Subscribe to Selected New Research on Glucose

51711 relevant articles (1934 outcomes, 5863 trials/studies) found for this Drug

Description: A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.

Also Known As:

Dextrose; D-Glucose; L-Glucose; Glucose Monohydrate; Glucose, (DL)-Isomer; Glucose, (L)-Isomer; Glucose, (alpha-D)-Isomer; Glucose, (beta-D)-Isomer; D Glucose; L Glucose; Monohydrate, Glucose

Relationship Network

Drug Context: Research Results

Krebs-Henseleit solution: 229

Bretschneider cardioplegic solution: 59

World Health Organization oral rehydration solution: 47

5-thio-D-glucose: 29

glucose-insulin-potassium cardioplegic solution: 21

allose: 18

invert sugar: 18

ADSOL: 15

TES-Tris yolk buffer: 14

acid citrate dextrose: 13

CPDA solutions: 11

citrate phosphate dextrose: 9

low potassium dextran glucose solution: 7

medikhronal: 7

beta-D-glucosylisophosphoramide mustard: 6

benzylidene glucose: 5

2-deoxy-glucose tetraacetate: 3

deoxythymidine diphosphate-glucose: 3

Stanford cardioplegic solution: 3

1,6-anhydro-beta-glucopyranose: 2

clobenoside: 2

glucose-2-SNAP: 2

glucose-cysteine: 2

1,6-anhydro-3,4-dideoxyhex-3-enopyran-2-ulose: 1

N-glucopyranosylnicotinic acid: 1

WOG solution: 1

Y-ART 3: 1

(((1,2-5,6-di-O,O-isopropylideneglucofuranos-3-yl)oxocarbonyl)methyl)cobalt tricarbonyl triphenylphosphine

1,2,3,4-tetraacetoxy-5-(acetoxymethyl)cyclohexane

1,2,3,6-tetragalloylglucose

1,2,3-tri-O-galloylglucose

1,2-5,6-di-O-isopropylidene-D-glucofuranose

1,2-5,6-di-O-isopropylideneglucofuranosyl propanesulfinate

1,2-O-isopropylidene-D-glucofuranose

1,3,6-tri-O-galloylglucose

1,6-di-O-galloyl-beta-D-glucose

1-fluoroglucopyranosyl fluoride

1-O-galloyl-6-O-luteoyl-alpha-D-glucose

1-O-methyl-2,3-di-O-galloylglucose

1-O-methyl-6-O-caffeoylglucopyranose

1-O-octadecyl-2-O-methylglycerol-3-glucopyranoside

2,3,4,5,6-pentagalloylglucose

2,3,4,6-tetra-O-acetyl-1-thioglucopyranose

2,3,4,6-tetra-O-acetylglucopyranosyl bromide

2,4,6-tri-O-galloylglucose

2-deoxy-2-(3-hydroxybutyramido)-glucose

2-epsilon-lysino-2-deoxy-6-phosphoglucose

2-methyl-(3,4,6-tri-O-acetyl-1,2-dideoxyglucopyrano)(2,1-d)-2-oxazoline

2-O-carboxymethylglucose

3,5-O-benzylidene-1,2-O-isopropylideneglucofuranose

3,6-anhydroglucose

3,6-dideoxy-3-(3-hydroxybutyramido)glucose

3,9-dibromo-12-(4-O-methylglucopyranosyl)-6,7.12,13-tetrahydroindolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7-dione

3-deoxy-3,3-aziglucopyranose

3-deoxy-3-iodo-D-glucose

3-O-(2-iodoethyl)glucose

3-O-benzyl-6-O-pivaloylglucopyranose 1,2,4-orthopivalate

4'-dehydroxyphlorizin

4,6-O-(2'-iodoethylidene)glucose

4,6-O-(4'-iodoethylidene)glucose

4,6-O-benzylidene-D-glucopyranose

4,6-O-isoterchebuloylglucose

4,6-pyruvylated glucose

4-(2-fluoroethyl)-1-glucopyranosyl-1H-1,2,3-triazole

4-ketoglucose

5-fluoroglucopyranosyl fluoride

5-hydroxymethyl-1,2,3,4-cyclohexanetetrol

6,6-dideuteroglucose

6-C-glucosylaronadendrin

6-C-glucosylnalingenin

6-octanoylglucose

AS-3 preservative solution

beta-D-glucopyranosyl bismethoxyphosphoramidate

beta-D-glucopyranosyl isothiocyanate

CP 11EB

cytidine diphosphate-glucose

D-glucofuranose cyclic 1,2-3,5 bis(butylboronate)-6-acetate

dextrose albumin solution

diacetone glucose butyrate

dTDP-6-deoxy-4-ketoglucose

esterbut-6

ethylidene glucose

fattiviracin A1

gem-difluorocarba-D-glucose

Glc-Spheron

glucoerucin

glucofructan

glucopyranose spirohydantoin

glucose 6-(hydrogen sulfate)

Experts

1.	Zijlstra, Felix: 12 articles (08/2008 - 02/2003)
2.	van der Horst, Iwan C C: 12 articles (08/2008 - 02/2003)
3.	Malmberg, Klas: 12 articles (01/2008 - 06/2002)
4.	Rydén, Lars: 10 articles (01/2008 - 06/2002)
5.	Shaw, Jonathan E: 9 articles (07/2008 - 05/2002)
6.	Phelps, Michael E: 9 articles (02/2008 - 03/2002)
7.	Tuomilehto, Jaakko: 9 articles (01/2008 - 07/2003)
8.	Czernin, Johannes: 8 articles (02/2008 - 03/2002)
9.	Chiasson, Jean-Louis: 8 articles (11/2007 - 07/2003)
10.	Zimmet, Paul Z: 7 articles (07/2008 - 05/2002)

Related Diseases

1.	Insulin Resistance 03/18/2009 - "However, they caused a marked decrease of FBG and a significant improvement on glucose tolerance and insulin resistance in STZ-induced type 2 diabetic mice. " 10/01/2004 - "Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. " 03/01/1995 - "Despite these marked effects at the adipose cell level, glucose tolerance is not improved, probably due to insulin resistance in skeletal muscle and liver, where the transgene is not expressed. " 08/01/1991 - "High fat feeding causes insulin resistance and a marked decrease in the expression of glucose transporters (Glut 4) in fat cells of rats." 10/01/2008 - "Insulin resistance, measured by an intraperitoneal glucose tolerance test, of the treated rats was significantly improved along with an increase in the number of small differentiated adipocytes; however, epididymal fat mass decreased. " Order ALL the reference details at left...
2.	Body Weight (Weight, Body) 10/01/2008 - "In the RT-CGM group, there was a significant reduction in total daily calorie intake, weight, body mass index (BMI), and postprandial glucose level, and a significant increase in total exercise time per week after 3 months. " 03/01/2007 - "Administration of SDF fraction (0 x 5 g/kg body weight) to normal, type 1 or type 2 diabetic rats significantly improved oral glucose tolerance. " 07/01/2006 - "ovata (0.5 g/kg body weight) significantly improved glucose tolerance in normal, type 1 and type 2 diabetic rat models. " 08/01/2005 - "RESULTS: Supplementation of high-fat-containing chow with IHE reduced body weight gain and improved glucose tolerance in our experimental mice. " 12/01/2000 - "However, glucose tolerance was significantly improved and body weight was significantly increased in rhBTC-treated mice compared with untreated mice at 8 weeks. " Order ALL the reference details at left...
3.	Hyperglycemia 01/01/1987 - "Since hyperglycemia was improved when adipose tissue metabolism was unaltered, GH-dependent changes occurring in other tissues, such as liver or muscle, most likely contribute to derangements of glucose metabolism in diabetes, even when GH is not elevated. " 06/01/2006 - "There was rapid improvement in hepatic glucose effectiveness following only 3 h of NA infusion (NA3h = 31 +/- 6% suppression of EGP with hyperglycemia vs. NA- = 8 +/- 7%; P<0.01) and complete restoration of glucose effectiveness after 6 h of NA (NA6h = 41 +/- 8% suppression of EGP; P = NS vs. nondiabetic subjects). " 05/01/1992 - "We conclude that a marked decrease in whole-body, muscle, and nonoxidative glucose disposal can be induced by hyperglycemia alone." 02/01/2008 - "As opposed to earlier work that suggested that hyperglycemia in the acute clinical setting may be beneficial, it now appears that lower glucose levels are associated with improved outcomes. " 10/01/2007 - "The glucose infusion rate required to maintain hyperglycemia was significantly greater in POR (8.5 +/- 0.7 mgxkg(-1)xmin(-1), final 2 h) than in either CON or HAT (6.0 +/- 0.5 or 6.7 +/- 1.0 mgxkg(-1)xmin(-1), respectively). " Order ALL the reference details at left...
4.	Type 2 Diabetes Mellitus (MODY) 09/01/2004 - "Although there is widespread use of herbal dietary supplements that are believed to benefit type 2 diabetes mellitus, few have been proven to do so in properly designed randomized trials; their efficacy for intermediate-term glucose control remains unclear. " 11/01/1997 - "While the evidence is substantial that aerobic exercise training can reduce the risk of impaired glucose tolerance and NIDDM, the evidence that exercise training is beneficial in the treatment of NIDDM is not particularly strong. " 06/01/1996 - "Impaired glucose tolerance (IGT) male subjects showed significantly greater thickness of the intimal plus medial complex (IMT) than age-matched healthy males and showed no significant differences compared to age-matched NIDDM patients. " 02/21/1987 - "In contrast, the patients with non-insulin-dependent diabetes mellitus showed a significant improvement in their glucose tolerance, which paralleled the severity of their diabetes. " 01/01/1987 - "These sources were found to be potentially beneficial in the reduction of plasma glucose in non-insulin dependent diabetes mellitus subjects. " Order ALL the reference details at left...
5.	Weight Loss (Weight Reduction) 09/01/2002 - "Higher preoperative fasting glucose best predicted the decrease in TG; improved HOMA %S with weight loss correlated best with HDL-C. " 08/01/2009 - "Reduced skeletal muscle mitochondrial respiration and improved glucose metabolism in nondiabetic obese women during a very low calorie dietary intervention leading to rapid weight loss." 03/01/1990 - "After a 30-kg weight loss their glucose and lipid profiles were markedly improved but the thermic effect of glucose was still lower than that of the control subjects (4.2%, p less than 0.001). " 08/01/2009 - "In two phase II clinical trials, lixisenatide improved glucose tolerance, resulted in weight loss and lowered HbA1C, thereby causing significantly more patients to achieve target HbA1C levels compared with placebo. " 09/01/2009 - "Fasting glucose (-12%), systolic BP (-8.4 mm Hg), and diastolic BP (-7.0 mm Hg) were significantly improved in a subgroup of participants with at least 5% weight loss. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Blood Glucose (Blood Sugar)
3.	Cholesterol
4.	Potassium
5.	Metformin (Glucophage)
6.	Triglycerides (Triacylglycerol)
7.	Glucagon (Glukagon)
8.	Oxygen
9.	Leptin
10.	Lactic Acid

Related Therapies and Procedures

1.	Fluid Therapy (Oral Rehydration Therapy)
2.	Intravenous Infusions
3.	Injections
4.	Aftercare (After-Treatment)
5.	Oral Administration

Best Treatments:
Research Summary Report
on Insulin Resistance

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 979 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>